Clinical trial Enablement Accelevir’s focus on advancing assays for persistent HIV-1 and other viral infections, combined with partnerships with biopharma for translational research and early-stage clinical trials, presents a clear opportunity to upsell comprehensive assay development, validation services, and scalable workflows for clinical trials and translational studies.

Same-Day Processing The new Same-Day First Morning PBMC Processing service addresses high-demand, time-sensitive data quality needs at clinical sites. This capability can be positioned as a premium service to improve assay accuracy and turnaround, opening doors for pilot projects with biopharma partners requiring rapid, reliable PBMC workflows.

Financial Levers With a revenue range of 10–25 million and over 1.4 million in funding supporting growth, there is room to propose expansion of existing assay panels, additional validation studies, and co-development projects funded by government or pharma partnerships to accelerate commercialization.

Fully Integrated Stack Leveraging a tech stack that includes Google Cloud, iCIMS, and content platforms indicates readiness for scalable data management, secure collaboration, and partner portals. This can be leveraged to propose enterprise-grade data integration services, remote collaboration workflows, and reproducible assay reporting suites for sponsors.

Strategic Partnerships Active collaboration with academic and bio-pharma groups positions Accelevir to target joint development programs, translational research pilots, and early-stage trials. A proactive outreach plan to identify co-development and sponsored research opportunities could generate recurring revenue through multi-project engagements.